Publications:

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.

Nature Medicine

Ganan-Gomez, Irene I; Yang, Hui H; Ma, Feiyang F; Montalban-Bravo, Guillermo G; Thongon, Natthakan N; Marchica, Valentina V; Richard-Carpentier, Guillaume G; Chien, Kelly K; Manyam, Ganiraju G; Wang, Feng F; Alfonso, Ana A; Chen, Shuaitong S; Class, Caleb C; Kanagal-Shamanna, Rashmi R; Ingram, Justin P JP; Ogoti, Yamini Y; Rose, Ashley A; Loghavi, Sanam S; Lockyer, Pamela P; Cambo, Benedetta B; Muftuoglu, Muharrem M; Schneider, Sarah S; Adema, Vera V; McLellan, Michael M; Garza, John J; Marchesini, Matteo M; Giuliani, Nicola N; Pellegrini, Matteo M; Wang, Jing J; Walker, Jason J; Li, Ziyi Z; Takahashi, Koichi K; Leverson, Joel D JD; Bueso-Ramos, Carlos C; Andreeff, Michael M; Clise-Dwyer, Karen K; Garcia-Manero, Guillermo G; Colla, Simona S

Publication Date: 2022-03

Variant appearance in text: TET2: I1228F

PubMed Link: 35241842

Variant Present in the following documents:

• 41591_2022_1696_MOESM1_ESM.pdf
• 41591_2022_1696_MOESM3_ESM.xlsx, sheet 4

View BVdb publication page